Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

NCT03934216 PHASE2 COMPLETED Results posted

The purpose of this study is to assess the safety and efficacy of oral deucravacitinib in participants with moderate to severe ulcerative colitis (UC).

Details

Lead sponsor	Bristol-Myers Squibb
Phase	PHASE2
Status	COMPLETED
Enrolment	131
Start date	Mon Jul 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Ulcerative Colitis

Interventions

• BMS-986165
• Placebo

Countries

France, Italy, Japan, Russia, Belgium, United Kingdom, Germany, Hungary, Poland, South Korea, Australia, United States, Czechia